retatrutide trial results news Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide for weight loss: Study

Serious gastrointestinal disease: May cause GI adverse reactions

Minimizing distractions will help you and our provider communicate effectively

Calories in purchased foods dropped just -2kcal per 100g, sugar dropped by about half a gram per 100g, and protein increased slightly

Risk of cardiovascular outcomes in patients with type 2 diabetes after addition of SGLT2 inhibitors versus sulfonylureas to baseline GLP-1RA therapy

Energy Expenditure and Metabolic Rate Research Retatrutide's tri-agonist receptor activity also makes it relevant for research examining metabolic rate and energy expenditure pathways

The landscape of medical weight management in the United Kingdom has advanced rapidly, providing patients with more options than ever before